Cover Image
市場調查報告書

D型肝炎:開發中產品分析

Hepatitis D - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 245993
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
D型肝炎:開發中產品分析 Hepatitis D - Pipeline Review, H1 2018
出版日期: 2018年04月17日 內容資訊: 英文 60 Pages
簡介

所謂D型肝炎是受到D型肝炎病毒(HDV,三角洲病毒)感染,使肝臟腫起這樣的感染疾病。主要症狀有皮膚·眼球的黃疸和關節痛·腹痛,噁心,食慾不振,倦怠感等。主要風險要素包含大量輸血,及靜脈注射(IV)藥物·注射藥的濫用,妊娠中的感染等。

本報告提供全球各國治療D型肝炎所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

D型肝炎概要

治療藥的開發

  • D型肝炎開發中產品:概要
  • 各企業治療藥
  • 各大學/研究機關的治療藥
  • 開發中的產品一覽(各企業)
  • 開發中的產品一覽(各大學/研究機關)

D型肝炎:治療藥的評估

  • 標的別
  • 各作用機制
  • 各分子類型

D型肝炎開發治療藥的企業

  • Alnylam Pharmaceuticals Inc
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • Spring Bank Pharmaceuticals Inc

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10341IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H1 2018, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 4 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Hepatitis D - Overview
  • Hepatitis D - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Hepatitis D - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Hepatitis D - Companies Involved in Therapeutics Development
  • Eiger BioPharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • Globeimmune Inc
  • Merck & Co Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • SomaGenics Inc
  • Hepatitis D - Drug Profiles
  • Antisense RNAi Oligonucleotide for Hepatitis D - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GI-18000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lonafarnib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Myrcludex-B - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • peginterferon alfa-2a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • peginterferon lambda-1a - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RBT-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REP-2139 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REP-2165 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vanitaracin A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Hepatitis D - Dormant Projects
  • Hepatitis D - Product Development Milestones
  • Featured News & Press Releases
  • Apr 03, 2018: Replicor to Disclose Updated Data Demonstrating Functional Remission of HBV and HDV at the EASL International Liver Conference 2018
  • Apr 02, 2018: Eiger BioPharmaceuticals to Participate in Conferences in April
  • Mar 27, 2018: MYR Pharma Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) Meeting
  • Mar 21, 2018: Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
  • Mar 12, 2018: MYR Pharma Completes Clinical Trial of Myrcludex B in Chronic Hepatitis Delta
  • Mar 05, 2018: Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting
  • Feb 22, 2018: MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B
  • Dec 12, 2017: Replicor Announces Publication of its in vitro Study on NAP Activity in HDV
  • Nov 28, 2017: Maxwell Biotech Venture Funds Portfolio Company Hepatera Announces Positive Interim Results of Phase 2b Clinical Program of Myrcludex B
  • Oct 23, 2017: Eiger Presents Data on Lonafarnib at the American Association for the Study of Liver Diseases Meeting
  • Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting
  • Oct 04, 2017: MYR GmbH Announces Presentation of Interim Results of Phase 2b Clinical Program of Myrcludex B at the American Association for the Study of Liver Diseases Conference
  • Sep 28, 2017: Replicor Announces Publication of its REP 301 Study in HBV / HDV Co-Infection in The Lancet Gastroenterology & Hepatology
  • Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
  • Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis D, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Hepatitis D - Pipeline by Eiger BioPharmaceuticals Inc, H1 2018
  • Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018
  • Hepatitis D - Pipeline by Globeimmune Inc, H1 2018
  • Hepatitis D - Pipeline by Merck & Co Inc, H1 2018
  • Hepatitis D - Pipeline by Replicor Inc, H1 2018
  • Hepatitis D - Pipeline by Rodos BioTarget GmbH, H1 2018
  • Hepatitis D - Pipeline by SomaGenics Inc, H1 2018
  • Hepatitis D - Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development for Hepatitis D, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products by argets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top